News

When an initial antibiotic failed to improve lung function with a pulmonary exacerbation, switching antibiotics did not lead to greater gains among adults or children with cystic fibrosis (CF), a study found. “It appears clear that regardless of antibiotic choice, there is a subset of patients who will be slow…

Adults with cystic fibrosis (CF) who live with recurrent nose and sinus inflammation — called chronic rhinosinusitis, or CRS — have a poor health-related quality of life (HRQoL), and need improved diagnosis and treatment, a large Canadian study concluded. These findings were especially true for patients who experienced severe…

Kaftrio (elexacaftor, tezacaftor, and ivacaftor) is safe and effective in children with cystic fibrosis (CF) ages 6 to 11 with specific genetic mutations and advanced lung disease, according to a small study. Findings showed the therapy improved children’s lung function and reduced the need for antibiotics. The children’s…

Wheezing — noisy breathing with a whistling sound — occurs in nearly three of every four preschool-aged children with cystic fibrosis (CF), and its presence at age 6 is linked to worse lung function, a French study has found. Researchers also observed that the majority of older children and…

Lupin has received tentative approval from the U.S. Food and Drug Administration (FDA) to market ivacaftor tablets, a generic version of the cystic fibrosis (CF) therapy Kalydeco. The company’s request came in the form of an abbreviated new drug application (ANDA), containing data submitted for review and approval…

A pediatric gastroenterologist in Missouri has been awarded a $50,000 grant to open a study into the potential of an FDA-approved nonsurgical device, called IB-Stim, as a way of easing abdominal pain in children with cystic fibrosis (CF). The grant, by the Institute of…

Treatment with Kalydeco (ivacaftor) led to improved lung function and weight gain as well as fewer respiratory infections and hospitalizations among cystic fibrosis (CF) patients with certain CFTR gating mutations, according to a real-world study. “These results support the long-term effectiveness and use of ivacaftor [Kalydeco] for the…

Instead of stopping Trikafta treatment, reducing the dose and providing psychological support may reduce or resolve mental health side effects, including depression, anxiety, and brain fog in patients with cystic fibrosis (CF), a new study reports. “It was reassuring that dose adjustments, in conjunction with psychological support and…

Treatment with PP-007 — a compound known to promote the release of anti-inflammatory carbon monoxide (CO) gas — significantly reduced the levels of pro-inflammatory immune cells and molecules in the lungs of a mouse model of cystic fibrosis (CF), a study shows. These benefits were associated with an increased production…

Stool consistency and frequency were healthy for the majority of infants with cystic fibrosis (CF) in the first year of life, according to an analysis of data from the BONUS study. Stool consistency and frequency were not associated with pain, while infants exclusively fed with formula or who received…